• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
COVID-19 and high-efficacy multiple sclerosis therapies: Time for business as usual?新型冠状病毒肺炎与高效多发性硬化症疗法：一切照旧的时候到了吗？
Mult Scler. 2020 Sep;26(10):1267. doi: 10.1177/1352458520948211. Epub 2020 Aug 7.
2
COVID-19 pneumonia in a multiple sclerosis patient with severe lymphopenia due to recent cladribine treatment.新冠病毒肺炎在一名多发性硬化症患者中发作，该患者由于最近接受克拉屈滨治疗而出现严重的淋巴细胞减少症。
Mult Scler. 2020 Sep;26(10):1264-1266. doi: 10.1177/1352458520943783. Epub 2020 Aug 7.
3
Mild or no COVID-19 symptoms in cladribine-treated multiple sclerosis: Two cases and implications for clinical practice. cladribine 治疗多发性硬化症的轻度或无 COVID-19 症状：两例病例及对临床实践的影响。
Mult Scler Relat Disord. 2020 Oct;45:102452. doi: 10.1016/j.msard.2020.102452. Epub 2020 Aug 16.
4
Implications of COVID-19 Outbreak on Immune Therapies in Multiple Sclerosis Patients-Lessons Learned From SARS and MERS.COVID-19 疫情对多发性硬化症患者免疫治疗的影响——从 SARS 和 MERS 中吸取的教训。
Front Immunol. 2020 May 12;11:1059. doi: 10.3389/fimmu.2020.01059. eCollection 2020.
5
Response of the multiple sclerosis community to COVID-19.多发性硬化症群体对2019冠状病毒病的反应。
Mult Scler. 2020 Sep;26(10):1134-1136. doi: 10.1177/1352458520948748.
6
Treatment of multiple sclerosis under the COVID-19 pandemic.新冠疫情下的多发性硬化症治疗
Tidsskr Nor Laegeforen. 2020 Apr 29;140(8). doi: 10.4045/tidsskr.20.0333. Print 2020 May 26.
7
Rehabilitation Recommendations for Multiple Sclerosis Patients during the COVID-19 Pandemic.新冠疫情期间多发性硬化症患者的康复建议
Arch Iran Med. 2020 Jul 1;23(7):509-510. doi: 10.34172/aim.2020.51.
8
Characteristics of COVID-19 disease in multiple sclerosis patients.多发性硬化症患者的新冠肺炎疾病特征
Mult Scler Relat Disord. 2020 Oct;45:102276. doi: 10.1016/j.msard.2020.102276. Epub 2020 Jun 8.
9
The COVID-19 pandemic and the use of MS disease-modifying therapies.新冠疫情与多发性硬化症疾病修正疗法的使用
Mult Scler Relat Disord. 2020 Apr;39:102073. doi: 10.1016/j.msard.2020.102073. Epub 2020 Mar 27.
10
The big challenge for neurologists in treating patients with multiple sclerosis in the post-COVID-19 era.在新冠疫情后时代，神经科医生治疗多发性硬化症患者面临的巨大挑战。
Mult Scler Relat Disord. 2020 Jul;42:102170. doi: 10.1016/j.msard.2020.102170. Epub 2020 May 1.

引用本文的文献

1
The Immunological Therapeutic Strategies for Controlling Multiple Sclerosis: Considerations during the COVID-19 Pandemic.控制多发性硬化症的免疫治疗策略：COVID-19 大流行期间的考虑因素。
Biomolecules. 2021 Sep 17;11(9):1372. doi: 10.3390/biom11091372.
2
COVID-19 severity and outcome in multiple sclerosis: Results of a national, registry-based, matched cohort study.COVID-19 严重程度和多发性硬化症结局：一项全国性、基于登记、匹配队列研究的结果。
Mult Scler Relat Disord. 2021 Oct;55:103217. doi: 10.1016/j.msard.2021.103217. Epub 2021 Aug 16.
3
Rituximab and risk of COVID-19 infection and its severity in patients with MS and NMOSD.利妥昔单抗治疗多发性硬化症和 NMOSD 患者与 COVID-19 感染及其严重程度的风险。
BMC Neurol. 2021 May 1;21(1):183. doi: 10.1186/s12883-021-02218-4.
4
Response of the multiple sclerosis community to COVID-19.多发性硬化症群体对2019冠状病毒病的反应。
Mult Scler. 2020 Sep;26(10):1134-1136. doi: 10.1177/1352458520948748.

本文引用的文献

1
Recovery from COVID-19 in a B-cell-depleted multiple sclerosis patient.COVID-19 康复：B 细胞耗竭型多发性硬化症患者的案例
Mult Scler. 2020 Sep;26(10):1261-1264. doi: 10.1177/1352458520943791. Epub 2020 Aug 7.
2
COVID-19 pneumonia in a multiple sclerosis patient with severe lymphopenia due to recent cladribine treatment.新冠病毒肺炎在一名多发性硬化症患者中发作，该患者由于最近接受克拉屈滨治疗而出现严重的淋巴细胞减少症。
Mult Scler. 2020 Sep;26(10):1264-1266. doi: 10.1177/1352458520943783. Epub 2020 Aug 7.
3
COVID-19 in 7 multiple sclerosis patients in treatment with ANTI-CD20 therapies.7 例接受抗 CD20 治疗的多发性硬化症患者合并 COVID-19。
Mult Scler Relat Disord. 2020 Sep;44:102306. doi: 10.1016/j.msard.2020.102306. Epub 2020 Jun 15.
4
Alemtuzumab in multiple sclerosis during the COVID-19 pandemic: A mild uncomplicated infection despite intense immunosuppression.阿仑单抗治疗新型冠状病毒肺炎大流行期间的多发性硬化症：尽管免疫抑制严重，但感染轻微且无并发症。
Mult Scler. 2020 Sep;26(10):1268-1269. doi: 10.1177/1352458520926459. Epub 2020 May 28.
5
An Italian programme for COVID-19 infection in multiple sclerosis.一项针对多发性硬化症患者新冠病毒感染情况的意大利项目。
Lancet Neurol. 2020 Jun;19(6):481-482. doi: 10.1016/S1474-4422(20)30147-2. Epub 2020 Apr 30.
6
Treating multiple sclerosis and neuromyelitis optica spectrum disorder during the COVID-19 pandemic.在2019冠状病毒病大流行期间治疗多发性硬化症和视神经脊髓炎谱系障碍。
Neurology. 2020 Jun 2;94(22):949-952. doi: 10.1212/WNL.0000000000009507. Epub 2020 Apr 2.

COVID-19 and high-efficacy multiple sclerosis therapies: Time for business as usual?

作者信息

Brownlee Wallace J

机构信息

Department of Neuroinflammation, Queen Square Multiple Sclerosis Centre, UCL Queen Square Institute of Neurology, London, UK/National Hospital for Neurology and Neurosurgery, Queen Square, London, UK.

出版信息

Mult Scler. 2020 Sep;26(10):1267. doi: 10.1177/1352458520948211. Epub 2020 Aug 7.

DOI:10.1177/1352458520948211
PMID:32762499
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7720354/
Abstract
摘要